CA1201712A — Carbacyclin analogs
Assigned to Pharmacia and Upjohn Co · Expires 1986-03-11 · 40y expired
What this patent protects
ABSTRACT The present specification provides novel analogs of carbacyclin (CBA2), 6a-carba-prostacyclin (6a-carba-PGI2), which have pronounced prostacyclin-like pharmacological activity, e.g., as platelet anti-aggregatory agents. Specifically the novel chemical analogs…
USPTO Abstract
ABSTRACT The present specification provides novel analogs of carbacyclin (CBA2), 6a-carba-prostacyclin (6a-carba-PGI2), which have pronounced prostacyclin-like pharmacological activity, e.g., as platelet anti-aggregatory agents. Specifically the novel chemical analogs of CBA2 are those substituted by fluoro (C-5), alkyl (C-9), interphenylene (C-5), methano (C-6a,9), and an additional (olefinic) valence bond (C-6a,9). Further provided are benzindene analogs of CBA2 and sub-stituted forms thereof, i.e., 9-deoxy-2',9-methano (or 2',9-metheno)-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)-PGF1 compounds. Also provided are a variety of novel chemical intermediates, e.g., substi-tuted bicyclo[3.3.0]octane intermediates, and chemical process utilizing such intermediates which are useful in the preparation of the novel CBA2 analogs.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.